Recorded Presentations from the NCCN 2021 Virtual Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies™

The management of cancer is constantly evolving through the introduction of new advances related to cancer treatment and supportive care. This program will provide hematology/oncology nurses with comprehensive and clinically relevant information to optimize patient education and care. Information is focused on current and critical issues to provide hematology/oncology nurses with practical information that can be implemented in the practice setting.

Target Audience

This program is designed to meet the educational needs of hematology/oncology nurses and nurse practitioners who manage patients with hematologic malignancies.

Learning Objectives

The goal of this activity is to ensure that hematology/oncology nurses, as members of the interprofessional oncology care team, have the knowledge and skills necessary to apply the standards of care to their practice and health care setting for patients with hematologic malignancies.

Following this program, participants should be able to:

  • Evaluate advances in the management of patients with hematologic malignancies and key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and apply appropriate treatment and supportive care strategies to optimize patient education and care.
  • Review issues related to: using technology to facilitate education for patients receiving transplantation; financial toxicity in the care of patients with hematologic malignancies; decreasing emergency department visits in patients who have received chemotherapy; treatment considerations for older patients with AML; and new treatment options in multiple myeloma.
Additional information
Supporters: 

This activity is supported by educational grants from:

  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Pfizer Inc.

This educational activity is supported by an educational grant from GlaxoSmithKline.

This educational activity is supported by a medical education grant from Karyopharm® Therapeutics.

Course summary
Course opens: 
11/01/2021
Course expires: 
11/01/2022
Cost:
$0.00

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, 
re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.

Janet Bagley, MS, RN, AOCNS
Penny Moore, DNP, RN, OCN, NEA-BC
Jennifer Peterson, MSN, RN, OCN, BMTCN

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Yi Lisa Hwa, APRN, CNP, DNP
Akcea Therapeutics, Inc.: Honoraria 
sanofi-aventis U.S.: Honoraria

Glen J. Peterson, RN, DNP, ACNP
AbbVie, Inc.: Product/Speakers’ Bureau

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

These activities are approved for nursing contact hours. Complete accreditation information is provided before each individual educational activity.

 
Status
Price
Title
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.
$0.00Included
Please login or register to take this course.

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing